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Abstract
Innate immune activation beyond the central nervous system is emerging as a vital component of the pathogenesis of
neurodegeneration. Huntington’s disease (HD) is a fatal neurodegenerative disorder caused by a CAG repeat expansion in the
huntingtin gene. The systemic innate immune system is thought to act as a modifier of disease progression; however, the
molecular mechanisms remain only partially understood. Here we use RNA-sequencing to perform whole transcriptome
analysis of primary monocytes from thirty manifest HD patients and thirty-three control subjects, cultured with and without
a proinflammatory stimulus. In contrast with previous studies that have required stimulation to elicit phenotypic abnormali-
ties, we demonstrate significant transcriptional differences in HD monocytes in their basal, unstimulated state. This includes
previously undetected increased resting expression of genes encoding numerous proinflammatory cytokines, such as IL6.
Further pathway analysis revealed widespread resting enrichment of proinflammatory functional gene sets, while upstream
regulator analysis coupled with Western blotting suggests that abnormal basal activation of the NFŒB pathway plays a key
role in mediating these transcriptional changes. That HD myeloid cells have a proinflammatory phenotype in the absence of
stimulation is consistent with a priming effect of mutant huntingtin, whereby basal dysfunction leads to an exaggerated in-
flammatory response once a stimulus is encountered. These data advance our understanding of mutant huntingtin patho-
genesis, establish resting myeloid cells as a key source of HD immune dysfunction, and further demonstrate the importance
of systemic immunity in the potential treatment of HD and the wider study of neurodegeneration.
†Present address: Immune Tolerance, Tumor Immunology Program, German Cancer Research Center, 69120 Heidelberg, Germany.
Received: March 30, 2016. Revised: May 3, 2016. Accepted: May 3, 2016
VC The Author (2016). Published by Oxford University Press on behalf of the Human Molecular Genetics.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
1
Human Molecular Genetics, 2016, Vol. 0, No. 0 1–12
doi: 10.1093/hmg/ddw142
Advance Access Publication Date: 11 May 2016
Original Article
 HMG Advance Access published June 1, 2016
 at U








Huntington’s disease (HD) is an incurable, autosomal dominant
neurodegenerative disorder that is caused by a CAG repeat ex-
pansion in exon 1 of the huntingtin (HTT) gene (1). An expansion
of 40 or more repeats is fully penetrant, resulting in production
of the mutant (m)HTT protein that is the primary cause of cellu-
lar death and dysfunction (2). The central nervous system has
traditionally been regarded as the primary site of HD pathology,
with patients suffering from a range of symptoms including
movement disorders, cognitive impairment and psychiatric dis-
turbance. However, it is apparent that HD is in fact a disease of
the whole body, with the mHTT protein being expressed in all
cells and tissues that have been studied (3). Patients are affected
by a range of peripheral pathologies including skeletal muscle
wasting (4), and there is mounting interest in the immune sys-
tem as a potential modifier of disease progression.
HD patients exhibit immune dysfunction both centrally, in
the form of microglial activation (5), and peripherally, where ele-
vated levels of proinflammatory mediators are detectable up to
16 years before the predicted onset of motor symptoms (6,7).
These phenomena have recently been found to be correlated,
suggesting a global immune response to the presence of mHTT
whereby central pathology is mirrored peripherally (8). The in-
nate immune system is thought to be the primary source of HD
immune dysfunction, with myeloid cells comprising circulating
monocytes and tissue macrophages the likely peripheral effector
cells (9). HD myeloid cells ex vivo are hyper-reactive, producing
significantly more IL-8 and TNFa following lipopolysaccharide
(LPS) stimulation (10), and also exhibit functional deficits in their
migratory and phagocytic capabilities (11,12). These changes
contrast with T lymphocytes of the adaptive immune system,
which do not display any intrinsic phenotypic defects as a result
of mHTT expression (13). Such alterations in the innate immune
system are mirrored in mouse models of HD (12), suggesting that
they are caused by a common pathological effect of mHTT ex-
pression. Indeed, several studies have demonstrated that mHTT
has a cell-autonomous effect on innate immune cell function,
and that immune activation in HD is not simply a secondary
response to neuronal pathology (10,14). For example, the hyper-
reactive phenotype of human HD myeloid cells is reversible
following HTT lowering with siRNA, while mHTT levels in pe-
ripheral immune cells correlate with disease burden scores in
HD patients (15). Importantly, the peripheral innate immune
system has been suggested to act as a modifier of HD progres-
sion. Dampening of the immune system using a peripherally re-
stricted CB2 agonist improves the phenotype of an HD mouse
model (16), as does the administration of a TNFa antagonist (17),
a KMO inhibitor (18) and bone marrow transplantation (19).
Although these data suggest that the study of the HD peripheral
immune system has disease relevance far beyond its uses as a
‘window’ into the brain, the mechanisms underlying HD im-
mune dysfunction remain incompletely understood.
To date, studies on peripheral HD myeloid cells have almost
exclusively demonstrated phenotypic abnormalities in response
to LPS stimulation (10,11), and there is very little information
available on whether these cells are also abnormal in their basal,
unstimulated state. Indeed, there is currently no evidence that HD
myeloid cells have increased resting expression of proinflamma-
tory cytokines (10,14). It is therefore unclear whether mHTT only
affects HD myeloid cells following stimulation, or if there is an un-
derlying mechanism producing resting dysfunction that is respon-
sible for the phenotypic changes seen once the cells are activated.
Mutant HTT has been found to have a cell-autonomous priming
effect on HD murine microglial cell lines (14), resulting in in-
creased proinflammatory gene expression in the absence of stim-
ulation. Although a similar effect is yet to be shown in primary
human cells, it raises the possibility that mHTT’s potential base-
line effects in HD myeloid cells are responsible for their hyper-
reactive response to stimulation. This has important implications
for targeting peripheral immunity as a therapeutic for HD, as in-
trinsic pathology is more likely to be treatable without the need to
time intervention to coincide with inflammatory events.
Regardless of whether mHTT’s pathogenic effects are innate or
only occur following stimulation, evidence will likely be detectable
as changes in the cellular transcriptome; if mHTT has a tonic
pathogenic effect then transcriptional changes should occur in
unstimulated, resting cells. Transcriptional dysregulation is a cen-
tral feature of HD pathogenesis, and has been consistently dem-
onstrated in a range of HD tissues (20,21). Such broad effects on
transcription could be caused by several underlying causative
mechanisms, including sequestration of transcription factors by
mHTT aggregates, impairment of transcription factor degradation
by the ubiquitin-proteasome system, changes in histone modifica-
tions and the direct binding of mHTT to DNA (22). Moreover, the
functions of upstream intracellular signalling pathways are likely
affected. Mutant HTT activates the NFjB signalling pathway via a
direct interaction with the IKK complex, a key regulator of the
NFjB family of transcription factors (23). This is associated with
hyper-reactivity in HD myeloid cells, which exhibit an exaggerated
and prolonged NFjB signalling response to LPS (10). However, it is
not clear whether HD myeloid cells also display increased NFŒB
activity in the resting state; this is likely key to determining
whether HD myeloid cells are also abnormal in the absence of
stimulation. Furthermore, signalling downstream of the LPS re-
ceptor TLR4 is complex, including as it does activation of signal-
ling pathways such as those involving the mitogen-activated
protein kinases (MAPKs) (24), the contribution of which to HD my-
eloid cell dysfunction is yet to be fully explored.
Previous gene expression studies have demonstrated numer-
ous transcriptional changes in HD peripheral blood cells (21,25,26),
but these have been largely carried out on heterogeneous cell pop-
ulations with varying transcriptional profiles, and have rarely
been validated between studies. Therefore, study of specific cell
populations using modern sequencing technology is required to
identify biologically relevant transcriptional changes associated
with mHTT expression. Here, we use RNA sequencing (RNA-Seq)
to investigate the human HD monocyte transcriptome under both
resting and LPS-stimulated conditions. We demonstrate that the
transcriptome of HD myeloid cells is abnormal even in the ab-
sence of stimulation, including previously unreported increases in
the basal expression of proinflammatory cytokines. Pathway anal-
ysis to dissect the biological relevance of these expression changes
identifies numerous proinflammatory functional gene sets that
are altered in unstimulated HD myeloid cells, as well as specific
upstream regulator molecules that may be driving transcriptional
change; activation of potential regulator molecules is further in-
vestigated using Western blotting. These data provide new insight
into the pathogenesis of mHTT expression in systemic innate im-
mune cells, in addition to the potential for modulating the periph-
eral immune system to modify disease progression.
Results
HD monocytes exhibit resting proinflammatory
transcriptional changes
Although the phenotypic abnormalities associated with HD my-
eloid cells are relatively well characterized, considerably less is
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known about the transcriptional profile that underpins these
changes. To address this, CD14þmonocytes were isolated from
peripheral blood samples donated by thirty manifest HD pa-
tients and thirty-three control subjects, and cultured with and
without stimulation with LPS and interferon gamma (IFN-c).
RNA-Seq of these samples was carried out to provide a quanti-
tative analysis of the entire HD monocyte transcriptome. LPS-
stimulation was confirmed by pooling the HD and control sam-
ples and performing differential expression analysis between
the unstimulated and stimulated datasets; 12 599 genes were
found to be differentially expressed (false discovery rate (FDR)
< 0.05; Dataset S1).
Differential expression analyses were then performed to de-
termine which genes are significantly altered between HD and
control monocytes, whereby the unstimulated and stimulated
monocytes were analysed separately. Analysis of the unstimu-
lated monocyte data identified 130 genes that were differen-
tially expressed (FDR < 0.05, 101 upregulated and 29
downregulated) in resting HD cells compared with control
(Table 1; Dataset S2). Although the differentially expressed
genes were associated with a wide range of effector functions,
proinflammatory cytokines and chemokines were heavily fea-
tured, with HD monocytes having significantly increased ex-
pression of IL6, IL12B, IL19, IL23A, CCL8, CCL19, CCL20, CXCL6 and
CSF2 gene transcripts. All of these genes had a log2 fold change
of > 1, corresponding to a >2-fold increase in mRNA expression.
This contrasted with the stimulated dataset, which showed
comparatively little evidence of differential expression between
HD and control cells, as only DNAJB13, STAC and RASEF were
found to be differentially expressed (FDR < 0.05; Dataset S3).
Each of these genes were also found to be differentially ex-
pressed in the unstimulated dataset (these genes are displayed
as red dots in Fig. 1). Comparison of the log2 fold changes re-
vealed a general trend whereby the relative expression differ-
ences between HD and control were lower in the stimulated
compared with the unstimulated dataset; this was the case for
116 of the 130 differentially expressed genes (Fig. 1). This
observation of more profound change in resting HD monocytes
is in marked contrast to previous functional studies where a
stimulus has been necessary to elicit phenotypic differences
(10–12).
HD monocytes do not display significant changes in
alternative splicing
Next, we investigated whether changes in alternative splicing
underlie the expression differences seen in our dataset, as dif-
ferential splicing has been shown to be a key pathogenic mech-
anism in tissues from a number of neurodegenerative diseases,
including HD brain (27). However, analysis of individual exon,
intron and transcript levels showed no significant differences in
either the unstimulated or stimulated datasets (FDR < 0.05;
Datasets S4–S9). This suggests that, in contrast to other tissues,
differential splicing is not a major factor in mediating HD innate
immune dysfunction.
Proinflammatory functional gene sets are enriched in
resting HD monocytes
We next sought to assign biological relevance to the observed
expression changes by carrying out a comprehensive Gene Set
Enrichment Analysis (GSEA) of the unstimulated and stimulated
datasets. GSEA allows for the unbiased identification of clusters
of genes showing evidence of differential expression, without
relying on the genes being individually significant after correc-
tion for multiple testing; this enables relevant biological trends
to be uncovered. Over 14 000 functional gene sets drawn from
multiple sources (see Materials and Methods section) were
tested for enrichment; upregulated and downregulated genes
were evaluated separately. Analysis of the unstimulated dataset
revealed a total of 85 enriched gene sets (FDR < 0.05) amongst
the upregulated genes in resting HD monocytes (Fig. 2; Dataset
S10). Functional gene sets relating to innate immunity, the in-
flammatory response and cytokine production were heavily
Table 1. The top 20 gene expression changes in resting HD monocytes (ranked by FDR)







P-value FDR Protein function
FAM124A ENSG00000150510 0.242 0.812 2.684 4.61E-08 6.05E-04 Functionally uncharacterized
IL19 ENSG00000142224 0.586 1.473 2.358 1.15E-07 7.57E-04 Proinflammatory cytokine
IL23A ENSG00000110944 1.914 3.597 1.576 7.84E-07 2.55E-03 Proinflammatory cytokine
FAM213B ENSG00000157870 7.837 5.201 0.604 8.99E-07 2.55E-03 Prostaglandin metabolism
TGFA ENSG00000163235 0.665 1.392 1.550 9.69E-07 2.55E-03 Growth factor; promotes cell proliferation
FZD7 ENSG00000155760 0.397 0.246 0.721 1.39E-06 3.04E-03 Wnt protein receptor
C6orf223 ENSG00000181577 0.063 0.297 2.127 1.92E-06 3.60E-03 Functionally uncharacterized
PROCR ENSG00000101000 3.695 10.872 1.552 3.61E-06 5.69E-03 Receptor for activated protein C
NT5E ENSG00000135318 0.210 0.725 2.082 4.24E-06 5.69E-03 Hydrolyses extracellular nucleotides
SMO ENSG00000128602 0.259 0.124 1.161 4.33E-06 5.69E-03 G protein-coupled receptor
CISH ENSG00000114737 2.723 5.161 1.439 5.90E-06 7.04E-03 Negative regulation of JAK/STAT signalling
C6orf165 ENSG00000213204 0.038 0.086 1.205 6.57E-06 7.20E-03 Functionally uncharacterized
CCL19 ENSG00000172724 0.518 1.767 1.763 8.79E-06 8.89E-03 Chemoattraction of T and B lymphocytes
PTGS2 ENSG00000073756 2.319 18.604 1.813 9.52E-06 8.93E-03 Prostaglandin synthesis enzyme
HPSE ENSG00000173083 11.322 24.941 1.142 1.10E-05 9.68E-03 Extracellular matrix remodelling
VEGFA ENSG00000112715 5.475 14.251 0.898 1.35E-05 1.11E-02 Promotes angiogenesis and endothelial cell growth
ANXA11 ENSG00000122359 136.875 105.621 0.374 1.72E-05 1.33E-02 Phospholipid-binding protein
CDK2 ENSG00000123374 5.534 7.186 0.390 1.88E-05 1.39E-02 Cell cycle regulation
R3HCC1 ENSG00000104679 15.225 11.394 0.421 2.18E-05 1.45E-02 Nucleic acid binding
PGAP3 ENSG00000161395 2.943 2.310 0.364 2.28E-05 1.45E-02 GPI-specific phospholipase
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represented, while gene sets relating to the NFjB and JAK/STAT
intracellular signalling cascades were also found to be signifi-
cantly enriched. In contrast, amongst the downregulated genes
only six gene sets relating to vacuole, lysosome and catabolic
function were found to be significantly enriched (FDR < 0.05).
Analysis of the stimulated dataset did not reveal any enriched
gene sets among the upregulated genes (FDR < 0.05); this is con-
sistent with the loss of significance for individual genes de-
scribed earlier. However, 83 functional gene sets were found to
be significantly enriched among the downregulated genes
(Supplementary Material, Figure S1; Dataset S11); pathways re-
lating to translation, protein localization, cholesterol homeosta-
sis and cellular components including the cellular membrane,
mitochondria and lysosome were among the most affected.
Details of the genes contained in each significant gene set are
included in Dataset S12.
Specific upstream intracellular signalling pathways
appear to mediate basal differences in HD monocyte
gene expression
To increase our understanding of the mechanisms underlying
differential gene expression in resting HD monocytes, we per-
formed upstream regulator analysis on the unstimulated data-
set using Ingenuity pathway analysis (IPA) software. IPA
compares gene expression in a dataset with lists of genes that
are known to be regulated by specific upstream signalling mole-
cules, in order to infer whether a particular regulatory molecule
is likely to be activated or inhibited. It is important to note that
due to overlapping gene sets there is redundancy in the analy-
sis, and that multiple points along a pathway may be suggested
as upstream regulators, even if only one is driving the change.
This effect is quantified by the activation z-score statistic, which
increases or decreases depending on the inferred activation/in-
hibition state of a particular upstream regulator.
Significance in IPA is typically attributed to upstream regula-
tors that have an overlap p-value of < 0.01 and an activation
z-score of > 2 or <2; 155 upstream regulators fulfilled these cri-
teria in our unstimulated dataset (Table 2; Dataset S13). Of
these, 125 were predicted to be significantly activated, while
thirty were predicted to be significantly inhibited. Due to the re-
dundancy associated with IPA it is unlikely that this many are
actually affected, so we decided to narrow our focus to the sub-
set of upstream regulators with the highest activation z-scores,
and therefore the strongest evidence for their mediating tran-
scriptional dysregulation. Crucially, a large number of mole-
cules associated with intracellular signalling pathways
downstream of the TLR4 receptor were represented in this
group (Fig. 3). Consistent with previous data showing NFjB dys-
regulation in HD myeloid cells, both RELA and the NFjB com-
plex were featured in the top ten most significant results
ranked by activation z-score. Other notable potential regulators
included NFjB1, the ERK and p38 MAPKs, in addition to the tran-
scription factor STAT3. These data suggests that the transcrip-
tional changes observed in the RNA-Seq dataset are related to
the abnormal activation of specific upstream signalling mole-
cules responsible for driving gene expression in resting HD mye-
loid cells.
NFŒB but not ERK or p38 MAPK signalling is abnormally
activated in resting HD myeloid cells
Previously we demonstrated that HD myeloid cells exhibit an
exaggerated NFjB signalling response to LPS, both in the magni-
tude of the initial activation and the prolonged time taken for
activation to return to baseline (10). However, it is unclear
whether NFŒB dysfunction also extends to the cells in their
basal, resting state. To follow up the upstream regulator analy-
sis, we next investigated whether the NFŒB pathway is abnor-
mally activated in unstimulated HD myeloid cells. Monocyte-
derived macrophages were obtained from manifest HD and con-
trol subjects, before Western blotting was carried out to quan-
tify the expression of IŒBa. IŒBa is a cytoplasmic inhibitor of the
NFŒB family of transcription factors; lower IŒBa levels are used
to demonstrate increased NFŒB activity, as reduced inhibition
will lead to increased translocation of NFŒB to the nucleus.
Consistent with the upstream regulator analysis, we found that
resting HD myeloid cells express significantly less IŒBa than
control cells (Fig. 4). This demonstrates that the abnormal NFŒB
activity previously described in stimulated HD myeloid cells
also exists basally.
However, the contribution of alternative signalling pathways
to HD myeloid cell dysfunction is yet to be fully characterized.
The ERK and p38 MAPKs were selected for investigation as they
both play a major role in signalling downstream of the LPS re-
ceptor TLR4 (24), and were identified by IPA as potentially signif-
icant transcriptional regulators in resting HD monocytes. ERK
and p38 are both activated by phosphorylation; quantification
of phosphorylated relative to total protein therefore allows their
activation states to be investigated. Monocyte-derived macro-
phages were obtained from manifest HD and control subjects,
before cells from each subject were pulsed with LPS and IFN-c
for 15, 30, 60 and 120 min, or left unstimulated. Western blotting
Figure 1. Comparison of log2 fold changes in resting and stimulated HD and con-
trol monocytes. The log2 fold changes for the 130 differentially expressed genes
in resting HD monocytes (FDR < 0.05) were compared between the unstimulated
and stimulated datasets. The magnitude of the relative expression difference
was greater in the unstimulated samples for 116 of these genes, suggesting that
transcriptional differences between HD and control monocytes become less pro-
nounced in response to stimulation. Genes which were only differentially ex-
pressed in the unstimulated samples are shown in blue, while the three genes
which were differentially expressed in both datasets are shown in red. HTT is
further shown in green, while the NFŒB transcription factor RELA (p65) is shown
in purple (however neither of these genes were differentially expressed). The
line x¼ y is also shown.
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to quantify the expression of the total and active, phosphory-
lated forms of both ERK and p38 showed no significant differ-
ences in activation either basally or at any of the time points
following LPS stimulation. Furthermore, no significant differ-
ences were seen in the expression of total ERK or p38 compared
with the reference protein b-actin. This suggests that, in con-
trast to NFjB, HD myeloid cells do not exhibit abnormally acti-
vated ERK or p38 signalling, and that these pathways are
unlikely to drive the transcriptional changes seen in the RNA-
Seq dataset.
Discussion
Previous studies of peripheral HD myeloid cells have primarily
demonstrated phenotypic dysfunction in the stimulated state
(10–12). In contrast, very little is known about the extent to
which these cells also display abnormalities in their basal, rest-
ing state. Here, use of RNA-Seq demonstrates that the basal
transcriptome of resting HD monocytes is significantly altered,
suggesting that mHTT expression has a state-independent ef-
fect occurring via a mechanism that is not restricted to the dys-
regulation of intracellular signalling pathways following
stimulation. This has previously been shown in a wide range of
tissues including brain, skeletal muscle and whole blood (22),
reinforcing the observation that mHTT consistently affects the
basal transcriptome in both patients and animal models of HD.
Crucially, HD monocytes expressed basally elevated levels of
numerous proinflammatory cytokine gene transcripts, for the
first time showing increased resting cytokine expression at ei-
ther the mRNA or protein level. HD patients have elevated levels
of cytokines and chemokines in their peripheral blood, with in-
creased IL-6 being detectable up to 16 years before the predicted
onset of motor symptoms (6,7); the upregulated IL6 expression
seen in our dataset strongly suggests that peripheral myeloid
cells are a key source. The existence of proinflammatory tran-
scriptional changes in the absence of stimulation was con-
firmed by GSEA, whereby significant enrichment of numerous
functional gene sets relating to innate immunity, inflammation
and cytokine production was found in resting HD monocytes.
This is important as it allows us to assign wider biological rele-
vance to the expression changes seen in our dataset, while
avoiding any investigator bias that could occur from looking at
specific genes in isolation. Consistent with a previous RNA-Seq
study on post-mortem brain, we also found that the majority of
Figure 2. Functional gene sets associated with innate immunity and inflammation are enriched in resting HD monocytes. GSEA identified biologically relevant gene
sets that are enriched in resting HD monocytes. A network diagram of significant biological themes among the upregulated genes is shown, indicating number of genes
(node size), statistical significance (darkest shading¼ lowest P-value) and gene content similarity via the Jaccard coefficient (edge thickness). Nodes with similar gene
content cluster more closely due to an edge-weighted layout (modified for readability). An FDR cut-off of<0.05 was used to determine gene set inclusion in the dia-
gram, before the Jaccard coefficient was used to filter out gene sets with similar gene content. The diagram was rendered in Cytoscape 3.3.0.
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the transcriptional changes in HD monocytes involved upregu-
lation (30).
Mutant HTT expression has been shown to promote cell-
autonomous dysfunction in murine microglial cultures and hu-
man monocyte models (10,14). Furthermore, in a murine HD
microglial line it has been suggested to prime resting cells,
whereby the enrichment of proinflammatory molecules in the
resting state leads to an exaggerated response once a stimulus
is encountered. This is thought to occur via increased expres-
sion of proinflammatory transcription factors including PU.1
(14). The transcriptional dysregulation we have demonstrated
in resting HD monocytes suggests that mHTT expression has a
similar priming effect on primary human myeloid cells. This is
a possible explanation for the increased cytokine release seen
after LPS stimulation (10), and may have significant relevance to
the pathobiology of HD in humans. Although HD patients have
elevated levels of circulating proinflammatory cytokines (6),
there is no evidence that they have an increased incidence of
infectious or inflammatory events. In addition, the phenotypic
improvement produced by modulation of the immune system
in animal models of HD is not dependent on ameliorating artifi-
cial inflammatory stimuli (16–18). This suggests that the proin-
flammatory peripheral changes observed in HD in vivo are not
dependent on, or primarily caused by, excessive cytokine








TNF 5.764 2.18E-13 Proinflammatory cytokine
IL1B 5.754 8.08E-14 Proinflammatory cytokine
MyD88 4.761 2.92E-12 Cytoplasmic adaptor protein for the TLR family
IFN-c 4.635 3.09E-07 Cytokine involved in mediating the innate immune response
IL1A 4.536 1.69E-11 Proinflammatory cytokine
TLR3 4.323 1.99E-09 Cell surface receptor involved in the activation of the innate immune response
RELA 4.122 5.86E-08 Transcription factor; one of five NFjB family members
NFjB (complex) 4.077 2.63E-08 A family of five transcription factors and their regulators that mediate the
inflammatory response
TLR9 3.773 4.33E-07 Cell surface receptor involved in the activation of the innate immune response
TLR2 3.770 3.94E-09 Cell surface receptor involved in the activation of the innate immune response
STAT3 3.701 2.34E-07 Transcription factor
IL6 3.654 7.39E-06 Proinflammatory cytokine
TICAM1/TRIF 3.651 2.59E-08 TLR cytoplasmic adaptor protein; mediates an alternative pathway to MyD88
ERK1/2 3.636 5.33E-06 Protein kinase intracellular signalling molecules
TLR4 3.610 7.68E-12 Cell surface receptor involved in the activation of the innate immune response
IPA was used to identify transcriptional regulators with significant target gene overlap with changes in the resting HD monocyte transcriptome. A P-value cut-off of
<0.01 was used to determine which genes were included in the analysis. The upstream regulators were ranked by activation z-score and the 15 most significant were
included in the table.
Figure 3. Specific intracellular signalling pathways are predicted to be abnormally activated in resting HD monocytes. IPA analysis of upstream regulators of gene tran-
scription identified numerous signalling pathway components downstream of the TLR4 receptor which are predicted to be abnormally activated in resting HD mono-
cytes. Upstream regulators with significantly inferred activation are shown in orange (darker colour¼higher activation z-score). The activation z-score for each
component is also shown (>2 or<2 is considered to be significant).
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release from repeatedly stimulated cells. Instead, a chronic in-
crease in the basal release of proinflammatory mediators allows
these observations to be reconciled independently of stimula-
tion. Furthermore, a number of the cytokines known to be upre-
gulated in HD peripheral blood are pre-synthesized in the
resting state. TNFa is synthesized as a membrane bound precur-
sor that is cleaved in response to stimulation (28), while IL-8
undergoes vesicular storage prior to release (29). Priming of HD
myeloid cells by mHTT could therefore cause increased cyto-
kine storage ready for release following stimulation, or indeed
increased basal release in the absence of stimulation. Indeed,
their increase in basal cytokine expression suggests that primed
myeloid cells are likely to have the latter effect. It is likely that
this phenomenon is also present in pre-manifest HD patients,
as immune changes including increased cytokine release are
detectable long before the onset of motor symptoms (6), and the
short life span of peripheral blood cells precludes the possibility
of a chronic effect built up over many years. This is supported
by the clear existence of intrinsic mHTT-related dysfunction in
HD myeloid cells, as it has been shown that peripheral immune
changes occur independently of neurodegeneration, and there-
fore are unlikely to be solely linked to advancing central disease.
The fact that numerous studies have demonstrated a disease-
modifying role for the peripheral immune system raises the
possibility that HD myeloid cells may even play a role in modi-
fying disease onset (16–19), but this will require further investi-
gation in mouse models of the disease.
Surprisingly, the transcriptome of stimulated HD monocytes
was comparatively unaffected in terms of differential gene ex-
pression. Comparison of the unstimulated and stimulated log2
fold changes revealed that, while the directions of effect were
largely consistent, the relative size of the majority of the fold
Figure 4. NFŒB but not ERK or p38 MAPK signalling is abnormally activated in resting HD myeloid cells. Monocyte-derived macrophages were isolated from HD and con-
trol peripheral blood samples and pulsed with LPS and IFN-c for 15, 30, 60 and 120 min, or left unstimulated. Western blotting was then carried out on the unstimulated
samples to quantify the basal levels of IŒBa, while additional Western blotting was carried out on all samples to quantify the levels of total and active, phosphorylated
ERK and p38 MAPK. (A) Resting HD myeloid cells express significantly reduced IŒBa protein compared with control (control n¼7, HD n¼9). However, no significant dif-
ferences were seen in (B) the ratio of phosphorylated to total enzyme, or (C) the ratio of total enzyme to b-actin for either ERK or p38 at any of the time points that were
studied (n¼10). Error bars represent6SEM, *P < 0.05.
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changes was reduced under stimulated conditions to the point
that they were no longer significant. This may be due to the ex-
tremely strong activating response provided by LPS, resulting in
a plateau in transcriptional activity as the cellular machinery
reaches the limits of its mRNA synthesis capability. This is
likely to result in the masking of biological differences between
HD and control monocytes, as the proinflammatory phenotype
displayed by resting HD monocytes is ablated by the stronger
inflammatory stimulus provided by LPS. Regardless, the lack of
differentially expressed genes in the stimulated samples sug-
gests that the proinflammatory transcriptional profile displayed
by resting HD monocytes is likely to be even more crucial in me-
diating their hyper-reactive response to LPS. Interestingly, a
number of gene sets were found to be enriched among the
downregulated genes in LPS-stimulated HD monocytes. The en-
richment for downregulation in numerous gene sets relating to
protein localization and targeting is consistent with known cy-
toskeletal defects in HD (30), while further enriched gene sets
were associated with organelles which are known to be affected
by mHTT, including the mitochondria and lysosome (31,32).
Although this analysis demonstrates that the transcriptome of
stimulated HD monocytes is affected by mHTT, the relative lack
of significant individual gene expression changes suggests this
gene set enrichment may not have the same biological signifi-
cance as that seen in resting HD myeloid cells.
Although this dataset suggests that mHTT expression has a
priming effect on the transcriptome of HD monocytes, under-
standing the underlying mechanism requires investigation of
the intracellular signalling pathways that are driving the tran-
scriptional changes. Previous work has demonstrated that
mHTT interacts directly with IKK, a key component of the NFjB
pathway (23). This results in reduced binding of NFjB by its cy-
toplasmic inhibitor IjB, leading to increased translocation of
NFjB to the nucleus and an increase in the expression of proin-
flammatory genes by HD myeloid cells (10). However, it was not
previously known whether this dysfunction also exists in the
resting state. Upstream regulator analysis using IPA inferred
highly significant basal activation of RELA, NFjB1 and the NFŒB
complex in resting HD monocytes. Furthermore, functional vali-
dation of IPA using Western blotting demonstrated that resting
HD myeloid cells express significantly reduced levels of the
NFŒB inhibitor IŒBa, showing that basal NFŒB signalling is also
affected in these cells. These data provide strong support for
the priming hypothesis, as the abnormal resting NFŒB activa-
tion by mHTT is likely to play a key role in mediating the proin-
flammatory transcriptional changes seen in the RNA-Seq
dataset.
As there is a considerable degree of redundancy in IPA it is
likely that the activation of a number of other upstream regula-
tors will have been inferred as a result of their target gene over-
lap with NFjB. Indeed, 13 of the top 15 inferred upstream
regulators ranked by activation z-score are known to be in-
volved in NFjB signalling (whether as an activating cytokine,
cell surface receptor or downstream transcription factor). This
conclusion is further supported by the GSEA analysis, which
identified an enrichment of genes relating to the NFŒB cascade
in resting HD monocytes. Other notable IPA hits included the
ERK and p38 MAPKs, and the transcription factor STAT3.
However, a previous study found no evidence of increased JAK/
STAT activation in HD monocytes (33), so it is likely that STAT3
activation was inferred as a result of its considerable target
gene overlap with NFjB (34). Furthermore, we carried out a
time-course experiment to examine the activation of the ERK
and p38 MAPKs in HD myeloid cells. Although we have
previously demonstrated that HD myeloid cells exhibit an exag-
gerated and prolonged NFjB activation response to LPS (10), no
such effect was seen for ERK or p38 either basally or in response
to LPS. Although this by no means rules out additional patho-
genic interactions of mHTT with the transcriptional machinery,
taken together these data further suggest that the transcrip-
tional changes observed in our dataset are likely to be due in
large part to resting dysregulation of the NFjB pathway.
However, it is important to note that not all transcriptional
changes observed in HD are pathological, as some may be com-
pensatory or even irrelevant (22). In addition, mHTT is known to
cause transcriptional dysregulation by a variety of mechanisms,
including but not limited to sequestration of transcription fac-
tors, chromatin remodelling and direct binding to DNA (22).
Therefore, it should not be expected that all of the expression
changes in our dataset will be explained by alterations in intra-
cellular signalling pathways, as some will presumably be the re-
sult of the myriad other effects of mHTT on the cellular
transcriptome. Despite this, upstream regulator analysis re-
mains an important tool for studying the biology of HD immune
cells, particularly when combined with established functional
data.
Furthermore, this study reinforces the conclusion that the
pre-eminent pathogenic mechanisms of mHTT may vary de-
pending on cell type. Increased expression of the transcription
factor PU.1 was found to mediate proinflammatory transcrip-
tional activation in a mouse microglial model of HD (14); how-
ever, neither that study not our current study revealed any
increase in PU.1 expression in HD patient monocytes.
Furthermore, activation of PU.1 in our dataset was not inferred
by IPA. Despite this, we have shown that resting HD monocytes
have a proinflammatory transcriptional profile which may be
caused by a similar mHTT priming effect to that seen in the mu-
rine HD microglial cell line. Although it has been suggested that
the separate developmental origins of microglia are responsible
for the prominent role of PU.1 (14), we also suggest that the rela-
tive importance of intracellular signalling pathways in different
cell types helps determine their varying contributions to HD
pathogenesis. The mechanism of mHTT interaction with each
signalling pathway seems unlikely to be drastically altered be-
tween cell types; this can be seen in the fact that NFjB binding
motifs were also found to be enriched in the HD microglial line
(14). However, as the PU.1 and NFjB pathways are vital for
microglial and monocyte/macrophage cell function, respec-
tively, it is not surprising that their dysregulation by mHTT will
cause them to have a central role in mediating mHTT-related
phenotypic dysfunction in these cell types. Conversely, cells
where these pathways have less important roles seem unlikely
to experience comparable dysfunction as a result of the same
mechanism, if indeed they are dysfunctional at all. Indeed, it
has been shown that the intrinsic function of HD T lymphocytes
is not affected by mHTT expression (13); it is possible that this is
due to the reduced importance of mHTT-affected signalling
pathways in mediating T lymphocyte function.
Finally, we demonstrate the importance of studying specific
cell populations using modern sequencing techniques and large
cohorts in order to accurately characterize HD-associated tran-
scriptional changes. Previous transcriptional studies of HD pe-
ripheral immune cells have investigated heterogeneous cell
populations with varying transcriptional profiles, and it has of-
ten not been possible to validate differentially expressed genes
between studies (21,25,26). The advent of high-throughput se-
quencing has provided dramatically improved coverage of the
entire transcriptome when compared with traditional
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microarrays, while the study of a single cell population allows
the noise associated with studying multiple cell populations
with varying transcriptional profiles to be eliminated. Although
the practical considerations associated with recruiting large pa-
tient cohorts are far from trivial, the importance of studying hu-
man tissues is demonstrated by the fact that genomic studies in
mice have been found to poorly mimic human inflammatory
conditions (35). The study of individual cell populations is also
particularly important given that a consistent transcriptional
signature has not yet been established between different HD tis-
sues (22), and observations made in one cell type may not hold
true when studying another.
This study therefore provides the first evidence of significant
basal proinflammatory changes in resting peripheral HD mye-
loid cells, with increased expression of proinflammatory cyto-
kine mRNA in addition to the enrichment of functional gene
sets associated with innate immunity, inflammation and cyto-
kine production. This suggests that mHTT primes HD myeloid
cells, resulting in an exaggerated proinflammatory response
once a stimulus is encountered. We show that previously de-
scribed NFŒB dysfunction also extends to resting HD myeloid
cells, and that abnormal activation of this pathway is likely to
play a key role in mediating their basal proinflammatory tran-
scriptional profile. However, the ERK and p38 MAPK pathways
do not appear to play a comparable role. The existence of basal
dysfunction further supports the possibility that modulation of
the innate immune system may be used as a therapeutic strat-
egy to modify HD progression, as the beneficial effects of immu-
nomodulatory drugs are likely to extend beyond ameliorating
the consequences of time-limited infectious or inflammatory
events. Finally, this study reinforces the importance of systemic
immunity in the wider study of neurodegeneration, as the exis-
tence of ex vivo myeloid cell abnormalities shows that periph-
eral tissues are in fact intrinsically abnormal, and are not
merely responding to central pathology.
Materials and Methods
Collection and classification of human samples
All experiments were performed in accordance with the
Declaration of Helsinki and approved by the University College
London (UCL)/UCL Hospitals Joint Research Ethics Committee.
Peripheral blood samples were donated by genetically diag-
nosed HD patients and control subjects, and all subjects pro-
vided informed written consent. HD subjects were classified by
their total functional capacity (TFC) score (36); only manifest
patients with early or moderate stage disease (TFC 13-3) were
included. The HD and control groups were age-matched
(Supplementary Material, Table S1), and all subjects who do-
nated samples for gene expression analysis were non-smokers
to control for the effects of smoking on the monocyte transcrip-
tome (37). Subjects with inflammatory or infectious conditions,
and those on immunomodulatory medications, were likewise
excluded from the study.
Isolation of human monocytes
Human peripheral blood mononuclear cells (PBMCs) were iso-
lated by density centrifugation. Peripheral blood samples were
layered on Histopaque-1077 (Sigma-Aldrich) and centrifuged at
400 g for 30 min. CD14þmonocytes were isolated by resus-
pending the PBMCs in 10 ml anti-human CD14 beads (Miltenyi
Biotec) and 90 ml MACS buffer (PBS with 1% BSA and 2 mM EDTA)
per 107 cells and incubating for 15 min at 4 C. Magnetic cell sort-
ing was carried out by placing MACS columns (Miltenyi Biotec)
in a magnetic field and adding each cell suspension to an indi-
vidual column. The columns were washed with MACS buffer be-
fore magnetically labelled CD14þmonocytes were eluted by
removing the columns from the magnetic field and plunging
MACS buffer through the column. The sorted cell populations
contained an average of 85–95% CD14þcells.
Cell culture and stimulation
Cells were cultured in RPMI 1640 culture medium supplemented
with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin and 50 mg/
ml streptomycin (Thermo Fisher Scientific). Monocytes were al-
lowed to rest for 16 h post-seeding before experimental use.
Monocyte-derived macrophages were obtained by supplement-
ing the culture medium with 20 ng/ml granulocyte macrophage-
colony stimulating factor (R&D Systems) for 6 days to induce
differentiation prior to experimental use. Monocyte cultures
were stimulated with 2 mg/ml LPS (Sigma-Aldrich) and 10 ng/ml
IFN-c (R&D Systems), while macrophage cultures were stimu-
lated with 1 mg/ml LPS and 10 ng/ml IFN-c. Monocyte stimula-
tion for RNA-Seq analysis was carried out for 4 h, as this has
previously been shown to be the peak time point for TLR4-
mediated gene activation following LPS stimulation (38,39).
RNA preparation and sequencing
RNA was extracted using the RNeasy Mini Kit (QIAGEN), includ-
ing the optional DNase step to prevent genomic DNA contami-
nation. RNA integrity was assessed using RNA 6000 Nano Chips
on a 2100 Bioanalyser (Agilent). Only samples with non-
degraded RNA (RIN  7) were used for sequencing. Sequencing
of RNA samples was performed by deCODE Genetics, Iceland.
Preparation of indexed cDNA sequencing libraries was carried
out using the TruSeq poly-A mRNA method (Illumina). Briefly,
poly-A mRNA transcripts were captured from total RNA using
poly-T beads, before cDNA was generated using random hex-
amer priming. Paired-end sequencing (2  100 cycles) of in-
dexed cDNA libraries was then carried out on a HiSeq 2500
machine (Illumina), generating at least 50 million reads (101
base pairs) per sample. Sequencing was performed using v4 SBS
and Cluster Kits (Illumina). One sample failed the library gener-
ation step and was excluded from the study. After sequencing
the indexed samples were demultiplexed before generation of
FASTQ files for analysis. Raw data files are available from the
European Nucleotide Archive (http://www.ebi.ac.uk/ena) under
the study accession number PRJEB12995.
Data processing and expression analysis
Data quality control was performed using the RNA-SeQC pack-
age (40). Metrics including rRNA rate, mapping rate, concor-
dance mapping rate and uniqueness rate were determined to
confirm that they were within acceptable parameters. One sam-
ple failed quality control and was removed from further analy-
sis. After quality control the remaining samples were aligned
using TopHat2 (41), before the counts were summarized using
HTSeq (keeping any read duplicates). Differential expression
analysis was then performed using the R package DESeq2 (42).
Outlier counts were removed using a Cooks distance cut-off of 5
in DESeq2 packages and gender was used as a covariate in the
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analysis. Differential splicing analysis was carried out on the
aligned data using the R package Ballgown (43).
Gene set enrichment analysis
Enrichment of differential expression among gene sets corre-
sponding to biological hypotheses (pathways) was tested using
the GSEA method (44). Rather than defining a list of significant
genes, GSEA ranks all genes in order of their differential expres-
sion statistic, and tests whether the genes in a particular gene
set have a higher rank overall than would be expected by
chance. The analysis is weighted by the differential expression
statistic, thus giving more weight to more significant genes.
Significance of enrichment was obtained by randomly permut-
ing gene-wide association statistics among genes. One-sided
p-values were calculated separately for differential upregulation
and downregulation of expression in HD, and these were then
converted into the corresponding chi-square statistic for use in
the GSEA analysis. To avoid making a priori assumptions, we
chose to use a large pathway set comprising Gene Ontology
(GO) (45), Kyoto Encyclopedia of Genes and Genomes (46),
PANTHER v8.1 (47), Mouse Genome Informatics (MGI) (48),
Reactome (49), Biocarta and NCIpathway interaction database
(50) pathways. This resulted in a total of 14 243 functional gene
sets, many with overlapping members, containing between 3
and 500 genes. To correct for multiple testing, we converted the
GSEA P-values into q-values (51), which can be interpreted as
the minimum false discovery rate (FDR) at which that q-value
would be counted as significant.
Upstream regulator analysis
Upstream regulator analysis was carried out using QIAGEN’s
IPA. IPA identifies potential upstream regulators of transcrip-
tional change using the P-value of overlap and activation
z-score statistics. The P-value of overlap uses Fisher’s exact test
to determine whether there is statistically significant overlap
between gene expression changes in a dataset and the genes
which are affected by an upstream regulator; significance is at-
tributed to molecules with a P-value of < 0.01. This does not
take the direction of expression changes into account, so the ac-
tivation z-score is used to predict whether potential upstream
regulators are activated or inhibited in the dataset. A z-score of
> 2 or<2 is generally considered to be significant. Further in-
formation on how the activation z-score is calculated is avail-
able on the IPA website (http://www.ingenuity.com/, Last
accessed March 29, 2016). A P-value cut-off of 0.01 was used to
determine which genes were included in the analysis.
Western blotting
Cells were lysed in RIPA buffer (25 mM Tris-HCl (pH 7.6), 150 mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS and 1X com-
plete protease inhibitor cocktail (Roche)), mixed with Laemmli
buffer and denatured at 95 C for 10 min. Lysates were run on
12% Tris-Glycine gels (Invitrogen) at 120 V, before transfer to 0.2
mm nitrocellulose membranes at 35 V for 2 h. Membranes were
blocked in 1:1 PBS/Odyssey Blocking Buffer (LI-COR) for 1 h be-
fore incubation with primary antibody diluted in 1:1 PBS/
Odyssey Blocking Buffer at 4 C overnight. Primary antibodies
used were to IŒBa (Santa Cruz Biotech; 1:500), p38, phospho-p38,
ERK (p42/44), phospho-ERK (p42/44) (all Cell Signalling
Technology; 1:1000) and b-actin (Abcam; 1:10000). After washing
with PBS the membranes were incubated with secondary anti-
body diluted in 1:1 PBS/Odyssey Blocking Buffer for 1 h.
Secondary antibodies used were IRDye 680RD Goat Anti-Mouse
IgG and IRDye 800CW Goat Anti-Rabbit IgG (LI-COR; 1:5000).
After washing the signal was visualized using an Odyssey
Infrared Imager (LI-COR) and quantified using TL100 software
(TotalLab).
Statistical analysis
Statistical analysis of differential expression, splicing, GSEA and
IPA data was carried out using the software packages outlined
above. IŒBa Western blotting was analysed using unpaired two-
tailed Student’s t-tests, while ERK and p38 MAPK Western blot-
ting experiments were analysed by two-way ANOVAs with
Bonferroni post-tests. All error bars represent SEM.
Supplementary Material
Supplementary Material is available at HMG online.
Acknowledgements
We would like to thank Lucy Carty and Salman Haider for their
help in collecting the samples, and Cardiff University Central
Biotechnology Services for their analytical support. We would
also like to thank the patients and control subjects who donated
samples and the staff of the multidisciplinary HD Clinic at the
National Hospital for Neurology and Neurosurgery, Queen
Square, London. This work was undertaken at UCLH/UCL who
acknowledge support from the Department of Health’s National
Institute for Health Research Biomedical Research Centre.
Conflict of Interest statement. None declared.
Funding
This study was funded by the EU FP7 Health Call (261358 and
305121 to S.J.T.); the Medical Research Council (MR/J003832/1 to
S.J.T., MR/L010305/1 to L.J. and PH, MR/L02053X/1 to R.A. and
S.J.T.); Rosetrees Trust (JS16/M220 to J.R.C.M.); CHDI (A-5053 to
T.C.S., A-9412 to S.J.T.); the National Institute for Health
Research University College London Hospitals Biomedical
Research Centre (BRC54/NS/RA and BRC230/NS/RA/101410 to
R.A.); and the Brain Research Trust (D.J.H.M.). Funding to pay
the Open Access publication charges for this article was pro-
vided by the Medical Research Council.
References
1. The Huntington’s Disease Collaborative Research Group.
(1993) A novel gene containing a trinucleotide repeat that is
expanded and unstable on Huntington’s disease chromo-
somes. Cell, 72, 971–983.
2. Ross, C.A. and Tabrizi, S.J. (2011) Huntington’s disease: from
molecular pathogenesis to clinical treatment. Lancet Neurol.,
10, 83–98.
3. Li, S.H., Schilling, G., Young, W.S., Li, X.J., Margolis, R.L.,
Stine, O.C., Wagster, M.V., Abbott, M.H., Franz, M.L. and
Ranen, N.G. (1993) Huntington’s disease gene (IT15) is widely
expressed in human and rat tissues. Neuron, 11, 985–993.
4. van der Burg, J.M., Bjo¨rkqvist, M. and Brundin, P. (2009)
Beyond the brain: widespread pathology in Huntington’s
disease. Lancet Neurol., 8, 765–774.
10 | Human Molecular Genetics, 2016, Vol. 0, No. 0
 at U







5. Tai, Y.F., Pavese, N., Gerhard, A., Tabrizi, S.J., Barker, R.A.,
Brooks, D.J. and Piccini, P. (2007) Microglial activation in pre-
symptomatic Huntington’s disease gene carriers. Brain, 130,
1759–1766.
6. Bjo¨rkqvist, M., Wild, E.J., Thiele, J., Silvestroni, A., Andre, R.,
Lahiri, N., Raibon, E., Lee, R.V., Benn, C.L., Soulet, D., et al.
(2008) A novel pathogenic pathway of immune activation
detectable before clinical onset in Huntington’s disease.
J. Exp. Med., 205, 1869–1877.
7. Wild, E., Magnusson, A., Lahiri, N., Krus, U., Orth, M.,
Tabrizi, S.J. and Bjo¨rkqvist, M. (2011) Abnormal peripheral
chemokine profile in Huntington’s disease. PLoS Curr., 3,
RRN1231.
8. Politis, M., Lahiri, N., Niccolini, F., Su, P., Wu, K., Giannetti, P.,
Scahill, R.I., Turkheimer, F.E., Tabrizi, S.J. and Piccini, P.
(2015) Increased central microglial activation associated
with peripheral cytokine levels in premanifest Huntington’s
disease gene carriers. Neurobiol. Dis., 83, 115–121.
9. Ellrichmann, G., Reick, C., Saft, C. and Linker, R.A. (2013) The
role of the immune system in Huntington’s disease. Clin.
Dev. Immunol., 2013, 541259.
10. Tr€ager, U., Andre, R., Lahiri, N., Magnusson-Lind, A., Weiss,
A., Grueninger, S., McKinnon, C., Sirinathsinghji, E., Kahlon,
S., Pfister, E.L. et al. (2014) HTT-lowering reverses
Huntington’s disease immune dysfunction caused by NFjB
pathway dysregulation. Brain, 137, 819–833.
11. Kwan, W., Tr€ager, U., Davalos, D., Chou, A., Bouchard, J.,
Andre, R., Miller, A., Weiss, A., Giorgini, F., Cheah, C. et al.
(2012) Mutant huntingtin impairs immune cell migration in
Huntington disease. J. Clin. Invest., 122, 4737–4747.
12. Tr€ager, U., Andre, R., Magnusson-Lind, A., Miller, J.R.,
Connolly, C., Weiss, A., Grueninger, S., Silajdzic, E., Smith,
D.L., Leavitt, B.R. et al. (2015) Characterisation of immune cell
function in fragment and full-length Huntington’s disease
mouse models. Neurobiol. Dis., 73, 388–398.
13. Miller, J.R., Tr€ager, U., Andre, R. and Tabrizi, S.J. (2015)
Mutant Huntingtin Does Not Affect the Intrinsic Phenotype
of Human Huntington’s Disease T Lymphocytes. PLoS One,
10, e0141793.
14. Crotti, A., Benner, C., Kerman, B.E., Gosselin, D., Lagier-
Tourenne, C., Zuccato, C., Cattaneo, E., Gage, F.H., Cleveland,
D.W. and Glass, C.K. (2014) Mutant Huntingtin promotes
autonomous microglia activation via myeloid lineage-
determining factors. Nat. Neurosci., 17, 513–521.
15. Weiss, A., Tr€ager, U., Wild, E.J., Grueninger, S., Farmer, R.,
Landles, C., Scahill, R.I., Lahiri, N., Haider, S., Macdonald, D.
et al. (2012) Mutant huntingtin fragmentation in immune
cells tracks Huntington’s disease progression. J. Clin. Invest.,
122, 3731–3736.
16. Bouchard, J., Truong, J., Bouchard, K., Dunkelberger, D.,
Desrayaud, S., Moussaoui, S., Tabrizi, S.J., Stella, N. and
Muchowski, P.J. (2012) Cannabinoid receptor 2 signaling in
peripheral immune cells modulates disease onset and se-
verity in mouse models of huntington’s disease. J. Neurosci.,
32, 18259–18268.
17. Hsiao, H.Y., Chiu, F.L., Chen, C.M., Wu, Y.R., Chen, H.M.,
Chen, Y.C., Kuo, H.C. and Chern, Y. (2014) Inhibition of solu-
ble tumor necrosis factor is therapeutic in Huntington’s dis-
ease. Hum. Mol. Genet., 23, 4328–4344.
18. Zwilling, D., Huang, S.Y., Sathyasaikumar, K.V., Notarangelo,
F.M., Guidetti, P., Wu, H.Q., Lee, J., Truong, J., Andrews-
Zwilling, Y., Hsieh, E.W. et al. (2011) Kynurenine 3-monooxy-
genase inhibition in blood ameliorates neurodegeneration.
Cell, 145, 863–874.
19. Kwan, W., Magnusson, A., Chou, A., Adame, A., Carson, M.J.,
Kohsaka, S., Masliah, E., Mo¨ller, T., Ransohoff, R., Tabrizi, S.J.
et al. (2012) Bone marrow transplantation confers modest
benefits in mouse models of Huntington’s disease.
J. Neurosci., 32, 133–142.
20. Hodges, A., Strand, A.D., Aragaki, A.K., Kuhn, A., Sengstag,
T., Hughes, G., Elliston, L.A., Hartog, C., Goldstein, D.R., Thu,
D. et al. (2006) Regional and cellular gene expression changes
in human Huntington’s disease brain. Hum. Mol. Genet., 15,
965–977.
21. Borovecki, F., Lovrecic, L., Zhou, J., Jeong, H., Then, F., Rosas,
H.D., Hersch, S.M., Hogarth, P., Bouzou, B., Jensen, R.V. et al.
(2005) Genome-wide expression profiling of human blood re-
veals biomarkers for Huntington’sdisease. Proc. Natl. Acad.
Sci. USA, 102, 11023–11028.
22. Seredenina, T. and Luthi-Carter, R. (2012) What have we
learned from gene expression profiles in Huntington’s dis-
ease? Neurobiol. Dis., 45, 83–98.
23. Khoshnan, A., Ko, J., Watkin, E.E., Paige, L.A., Reinhart, P.H.
and Patterson, P.H. (2004) Activation of the IkappaB kinase
complex and nuclear factor-kappaB contributes to mutant
huntingtin neurotoxicity. J. Neurosci., 24, 7999–8008.
24. Akira, S. and Takeda, K. (2004) Toll-like receptor signalling.
Nat. Rev. Immunol., 4, 499–511.
25. Runne, H., Kuhn, A., Wild, E.J., Pratyaksha, W., Kristiansen,
M., Isaacs, J.D., Re´gulier, E., Delorenzi, M., Tabrizi, S.J. and
Luthi-Carter, R. (2007) Analysis of potential transcriptomic
biomarkers for Huntington’s disease in peripheral blood.
Proc. Natl. Acad. Sci. USA, 104, 14424–14429.
26. Mastrokolias, A., Ariyurek, Y., Goeman, J.J., van Duijn, E.,
Roos, R.A., van der Mast, R.C., van Ommen, G.B., den
Dunnen, J.T., ’t Hoen, P.A. and van Roon-Mom, W.M. (2015)
Huntington’s disease biomarker progression profile identi-
fied by transcriptome sequencing in peripheral blood. Eur. J.
Hum. Genet., 23, 1349–1356.
27. Fernandez-Nogales, M., Cabrera, J.R., Santos-Galindo, M.,
Hoozemans, J.J., Ferrer, I., Rozemuller, A.J., Hernandez, F.,
Avila, J. and Lucas, J.J. (2014) Huntington’s disease is a four-
repeat tauopathy with tau nuclear rods. Nat. Med., 20,
881–885.
28. Black, R.A., Rauch, C.T., Kozlosky, C.J., Peschon, J.J., Slack,
J.L., Wolfson, M.F., Castner, B.J., Stocking, K.L., Reddy, P.,
Srinivasan, S. et al. (1997) A metalloproteinase disintegrin
that releases tumour-necrosis factor-alpha from cells.
Nature, 385, 729–733.
29. Lacy, P. and Stow, J.L. (2011) Cytokine release from innate
immune cells: association with diverse membrane traffick-
ing pathways. Blood, 118, 9–18.
30. Gunawardena, S., Her, L.S., Brusch, R.G., Laymon, R.A.,
Niesman, I.R., Gordesky-Gold, B., Sintasath, L., Bonini, N.M.
and Goldstein, L.S. (2003) Disruption of axonal transport by
loss of huntingtin or expression of pathogenic polyQ pro-
teins in Drosophila. Neuron, 40, 25–40.
31. Damiano, M., Galvan, L., De´glon, N. and Brouillet, E. (2010)
Mitochondria in Huntington’s disease. Biochim. Biophys.
Acta., 1802, 52–61.
32. Martin, D.D., Ladha, S., Ehrnhoefer, D.E. and Hayden, M.R.
(2015) Autophagy in Huntington disease and huntingtin in
autophagy. Trends Neurosci., 38, 26–35.
33. Tr€ager, U., Magnusson, A., Lahiri Swales, N., Wild, E., North,
J., Lowdell, M. and Bjo¨rkqvist, M. (2013) JAK/STAT signalling
in Huntington’s disease immune cells. PLoS Curr., 5.
34. Hoesel, B. and Schmid, J.A. (2013) The complexity of NF-jB
signaling in inflammation and cancer. Mol. Cancer, 12, 86.
11Human Molecular Genetics, 2016, Vol. 0, No. 0 |
 at U







35. Seok, J., Warren, H.S., Cuenca, A.G., Mindrinos, M.N., Baker,
H.V., Xu, W., Richards, D.R., McDonald-Smith, G.P., Gao, H.,
Hennessy, L. et al. (2013) Genomic responses in mouse mod-
els poorly mimic human inflammatory diseases. Proc. Natl.
Acad. Sci. USA, 110, 3507–3512.
36. Shoulson, I. (1981) Huntington disease: functional capacities
in patients treated with neuroleptic and antidepressant
drugs. Neurology, 31, 1333–1335.
37. Zeller, T., Wild, P., Szymczak, S., Rotival, M., Schillert, A.,
Castagne, R., Maouche, S., Germain, M., Lackner, K.,
Rossmann, H. et al. (2010) Genetics and beyond–the tran-
scriptome of human monocytes and disease susceptibility.
PLoS One, 5, e10693.
38. Aung, H.T., Schroder, K., Himes, S.R., Brion, K., van Zuylen,
W., Trieu, A., Suzuki, H., Hayashizaki, Y., Hume, D.A., Sweet,
M.J. et al. (2006) LPS regulates proinflammatory gene expres-
sion in macrophages by altering histone deacetylase expres-
sion. Faseb J., 20, 1315–1327.
39. Yamamoto, M., Yamazaki, S., Uematsu, S., Sato, S., Hemmi,
H., Hoshino, K., Kaisho, T., Kuwata, H., Takeuchi, O.,
Takeshige, K. et al. (2004) Regulation of Toll/IL-1-receptor-
mediated gene expression by the inducible nuclear protein
IkappaBzeta. Nature, 430, 218–222.
40. DeLuca, D.S., Levin, J.Z., Sivachenko, A., Fennell, T., Nazaire,
M.D., Williams, C., Reich, M., Winckler, W. and Getz, G. (2012)
RNA-SeQC: RNA-seq metrics for quality control and process
optimization. Bioinformatics, 28, 1530–1532.
41. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R. and
Salzberg, S.L. (2013) TopHat2: accurate alignment of tran-
scriptomes in the presence of insertions, deletions and gene
fusions. Genome Biol., 14, R36.
42. Love, M.I., Huber, W. and Anders, S. (2014) Moderated esti-
mation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol., 15, 550.
43. Frazee, A.C., Pertea, G., Jaffe, A.E., Langmead, B., Salzberg,
S.L. and Leek, J.T. (2015) Ballgown bridges the gap between
transcriptome assembly and expression analysis. Nat.
Biotechnol., 33, 243–246.
44. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S.,
Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub,
T.R., Lander, E.S. et al. (2005) Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide ex-
pression profiles. Proc. Natl. Acad. Sci. USA, 102, 15545–15550.
45. Harris, M.A., Clark, J., Ireland, A., Lomax, J., Ashburner, M.,
Foulger, R., Eilbeck, K., Lewis, S., Marshall, B., Mungall, C.
et al. (2004) The Gene Ontology (GO) database and informat-
ics resource. Nucleic Acids Res., 32, D258–D261.
46. Kanehisa, M., Goto, S., Sato, Y., Furumichi, M. and Tanabe, M.
(2012) KEGG for integration and interpretation of large-scale
molecular data sets. Nucleic Acids Res., 40, D1091–D1014.
47. Mi, H., Muruganujan, A. and Thomas, P.D. (2013) PANTHER
in 2013: modeling the evolution of gene function, and other
gene attributes, in the context of phylogenetic trees. Nucleic
Acids Res., 41, D377–D386.
48. Bult, C.J., Eppig, J.T., Kadin, J.A., Richardson, J.E., Blake, J.A.
and Group, M.G.D. (2008) The Mouse Genome Database
(MGD): mouse biology and model systems. Nucleic Acids Res.,
36, D724–D728.
49. Croft, D., Mundo, A.F., Haw, R., Milacic, M., Weiser, J., Wu, G.,
Caudy, M., Garapati, P., Gillespie, M., Kamdar, M.R. et al.
(2014) The Reactome pathway knowledgebase. Nucleic Acids
Res., 42, D472–D477.
50. Schaefer, C.F., Anthony, K., Krupa, S., Buchoff, J., Day, M.,
Hannay, T. and Buetow, K.H. (2009) PID: the Pathway
Interaction Database. Nucleic Acids Res., 37, D674–D679.
51. Storey, J.D. and Tibshirani, R. (2003) Statistical significance
for genomewide studies. Proc. Natl. Acad. Sci. USA, 100,
9440–9445.
12 | Human Molecular Genetics, 2016, Vol. 0, No. 0
 at U
niversity College London on July 12, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
